DEF: Predictive Oncology Seeks Reverse Split, $10M Equity Raise

Predictive Oncology Inc. calls a Special Meeting to approve a 1:15 reverse stock split and a $10 million equity raise to maintain Nasdaq listing compliance.

Summary

• Predictive Oncology Inc. is holding a Special Meeting of Stockholders on September 19, 2025, to vote on three key proposals.
• The first proposal is to approve a 1-for-15 reverse stock split of the company's common stock, primarily to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• The company received a delisting notice from Nasdaq on June 9, 2025, for failing to meet the $2,500,000 stockholders' equity requirement and another notice on July 8, 2025, for failing to meet the $1.00 minimum bid price requirement.
• Nasdaq granted an extension until December 8, 2025, for the company to demonstrate compliance with all listing requirements.
• The second proposal seeks stockholder approval for the issuance of up to $10,000,000 of common stock under a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., dated July 1, 2025, to comply with Nasdaq listing rule 5635.
• This approval is necessary to issue shares exceeding 19.99% of outstanding common stock or that could result in a change of control, as interpreted by Nasdaq.
• The SEPA allows the company to sell shares at a 4.0% discount to the volume-weighted average price (VWAP), with proceeds intended for working capital, general corporate purposes, and potential acquisitions.
• The third proposal is to approve the adjournment of the Special Meeting if there are insufficient votes to approve the reverse stock split or the SEPA proposals.
• As of the record date, August 18, 2025, there were 10,892,657 shares of common stock outstanding and entitled to vote. Post-reverse split, this would reduce to approximately 726,177 shares.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the underlying reasons for the proposals (Nasdaq non-compliance, need for dilutive capital). While the company is taking necessary steps to address these issues, the situation itself reflects significant challenges and potential for further dilution and stock price volatility.

Positives

• The company is proactively addressing Nasdaq listing deficiencies by proposing a reverse stock split and seeking approval for a significant equity financing facility.
• Maintaining Nasdaq listing is crucial for capital market access and investor perception, which these proposals aim to secure.
• The Standby Equity Purchase Agreement (SEPA) provides access to up to $10,000,000 in capital for working capital and strategic initiatives, offering financial flexibility.
• The Board of Directors unanimously recommends voting FOR all proposals, indicating strong internal alignment on these strategic actions.

Negatives

• The need for a reverse stock split indicates the company's stock price has fallen below Nasdaq's minimum bid price requirement, reflecting poor market performance.
• The company failed to regain compliance with Nasdaq's $2,500,000 stockholders' equity requirement within a previous 180-day extension period, leading to a delisting notice.
• The issuance of up to $10,000,000 in common stock through the SEPA will result in significant dilution for existing stockholders.
• There is no assurance that the reverse stock split will sufficiently increase the stock price or that the price will not decline again, potentially leading to further delisting threats under new Nasdaq rules.
• A reverse stock split may decrease stock liquidity and increase transaction costs for stockholders, particularly those holding odd lots.

Risks

• Failure to sufficiently increase stock price or complete the reverse stock split by December 8, 2025, could lead to delisting from Nasdaq.
• The stock price may not increase proportionately after the reverse split, or may decline due to other factors, reducing overall market capitalization.
• If the stock price falls below $1.00 within one year after the reverse split, Nasdaq will not grant a new compliance period, leading directly to delisting proceedings.
• Reduced number of outstanding shares post-split may decrease liquidity and result in higher transaction costs for investors.
• The effective increase in authorized shares due to the reverse split could be used to deter hostile takeover attempts, potentially limiting stockholder opportunities for a premium.
• The issuance of shares under the SEPA will dilute the economic and voting interests of existing stockholders.
• Inability to access the full $10,000,000 under the SEPA (if Nasdaq Proposal is not approved) could materially adversely affect the business and impede Nasdaq compliance.

Future Outlook

The company aims to regain and maintain compliance with Nasdaq listing requirements by December 8, 2025, through a reverse stock split and by securing capital via the Standby Equity Purchase Agreement. Proceeds from the SEPA are expected to fund working capital, general corporate purposes, and potential strategic investments or acquisitions, supporting future business opportunities and growth strategy.

Management Comments

• "After careful consideration, the Company's Board of Directors recommends a vote FOR the Reverse Split Proposal, FOR the Nasdaq Proposal, and FOR the Adjournment Proposal."
• "The Board believes that the Reverse Stock Split is necessary to assure compliance with the Minimum Bid Price Requirement."
• "The Board considers it important for the Company to maintain its Nasdaq listing. Delisting could adversely affect the trading market for the Company's common stock. Further, delisting would adversely affect the Company's ability to access the capital markets and pursue other financing alternatives."
• "We expect that any proceeds received by us from such sales to Yorkville will be used for working capital and general corporate purposes, and may also use proceeds to make capital expenditures, license or acquire intellectual property or technologies to incorporate into our products, or fund possible investments in and acquisitions of supplementary businesses, partnerships and minority investments."

Industry Context

The company operates in the oncology sector, a capital-intensive industry often reliant on public market access for funding research, development, and commercialization. The need for a reverse stock split and equity financing to maintain Nasdaq listing is a common challenge for smaller biotechnology or pharmaceutical companies that may experience stock price volatility and require ongoing capital infusions to sustain operations and growth initiatives.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• **Shareholders**: Will experience a reduction in the number of shares owned (1-for-15 reverse split) and significant dilution from the potential issuance of up to $10,000,000 in common stock under the SEPA. Fractional shares will be rounded up to whole shares. Maintaining Nasdaq listing could benefit liquidity and investor interest, but there's a risk of further price decline and increased transaction costs for odd lots.
• **Company Operations**: Access to up to $10,000,000 in capital from the SEPA will provide funding for working capital, general corporate purposes, and potential strategic investments, supporting ongoing operations and growth initiatives.
• **Regulatory Bodies (Nasdaq)**: The proposals are direct responses to Nasdaq's non-compliance notices, aiming to satisfy listing rules and avoid delisting, which is critical for regulatory standing.

Next Steps

• Hold a Special Meeting of Stockholders on September 19, 2025, to vote on the proposed reverse stock split, Standby Equity Purchase Agreement, and adjournment.
• File a Current Report on Form 8-K within four business days after the Special Meeting to announce the final voting results.
• Implement the reverse stock split (if approved) on the Reverse Split Effective Date, which will be the date of filing the Amendment with the Delaware Secretary of State or a later chosen date.
• Work to demonstrate compliance with all Nasdaq continued listing requirements, including the stockholders' equity and minimum bid price requirements, by December 8, 2025.
• Potentially utilize the Standby Equity Purchase Agreement to raise capital for working capital and general corporate purposes.

Key Dates

Recommendation

The company is taking necessary, albeit dilutive, steps to address critical Nasdaq listing deficiencies and secure capital. While the underlying situation (non-compliance, low stock price) is negative, these actions are essential to avoid delisting, which would be a more severe outcome. A 'hold' recommendation is appropriate for existing investors who believe in the long-term potential of the company's oncology business, as these measures are defensive and aimed at maintaining operational viability and market access. New investors should approach with caution due to the inherent risks and dilution.

Keywords

Reverse Stock Split, Nasdaq Compliance, Equity Purchase Agreement, Stock Dilution, Special Meeting, Oncology, Biotechnology, Capital Raise, Corporate Governance, POAI